🇺🇸 FDA
Patent

US 12239712

Combination therapy for the treatment of liver disease

granted A61KA61K31/192A61K31/198

Quick answer

US patent 12239712 (Combination therapy for the treatment of liver disease) held by GALMED RESEARCH AND DEVELOPMENT LTD expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GALMED RESEARCH AND DEVELOPMENT LTD
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/192, A61K31/198, A61K31/53, A61K31/575